Abstract
Hellström A, Nilsson AK, Wackernagel D, Pivodic A, Vanpee M, Sjöbom U, et al. Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr 2021:e205653. https://doi.org/10.1001/jamapediatrics.2020.5653 Among premature infants, what is the therapeutic benefit of supplemental arachidonic acid (AA) and docosahexaenoic acid (DHA), compared with no supplementation, in reducing the incidence of retinopathy of prematurity (ROP)? Randomized control trial. 3 centers in Sweden. Infants born <28 weeks' gestational age. AA:DHA vs none. Primary outcome: incidence of severe ROP (stage 3 and/or type 1 ROP). The treatment group demonstrated less ROP, 16 of 101 (15.8%) in the AA:DHA group vs 35 of 105 (33.3%) in the non-treatment group, absolute risk reduction 17.5% (6.0%-29.0%), number needed to treat 5.7 (3.5-16.6). There were no differences between the groups in bronchopulmonary dysplasia, intraventricular hemorrhage, sepsis, or death rates. AA:DHA reduced ROP development without increasing major morbidities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
